Ep. 148 - East-West Summit Highlights Part 2 - BioCentury This Week

Om avsnittet

As China’s biopharma companies experience their first “biotech winter,” they should be engaged in active portfolio management, stopping projects that will not meet their investors’ expectations, Agio Capital General Manager Henk Joos said on BioCentury This Week. On a special East-West Summit edition of the podcast, Joos and Immune-Onc Therapeutics founder and CEO Charlene Liao discussed pipeline prioritization and other company survival tactics during today’s difficult financing environment.

Reach us by sending a text

Ep. 148 - East-West Summit Highlights Part 2

Om avsnittet

Fler avsnitt

Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways

Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look

Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs

Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs

Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Ep. 384 - Back to School Special: The global FIH trials race

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA